Head-to-head · WeighScore
JRNYS vs Kin Meds
The verdict
Kin Meds takes it — 72.9/100 to 62.5/100.
Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | JRNYS | Kin Meds |
|---|---|---|
| WeighScore | 62.5/100 | 72.9/100 |
| Grade | C | C |
| Scorecard rank | #267 | #73 |
| Semaglutide | Not disclosed | $149/mo (brand Wegovy) |
| Tirzepatide | Not disclosed | $149/mo (brand Zepbound) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #267 · C
Strengths
- Branded, FDA-approved GLP-1s — Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda — rather than compounded copies
- The membership band is published before intake and is banded openly by level of coach support
- Medical visits, daily monitoring and 1-on-1 coaching are included in the membership at every tier
- Led by CMO Dr. Henry Legere (UC Berkeley, Columbia medicine, Harvard fellowship)
- Members with commercial insurance may pay around $25 a month for the medication after any deductible
Where it loses points
- The membership is overhead, not a medication price: it covers visits, monitoring and coaching, and the FAQ says medication pricing is confirmed only after a provider consultation
- No self-pay drug price is published anywhere, so the cost of a month cannot be worked out before signing up
- The best case depends on commercial insurance coverage; without it the medication cost is unknown
- No compounded option is disclosed — the programme is brand-focused, and brand list prices are the dearest route to a GLP-1
- The states it can prescribe in are not published
Graded #73 · C
Strengths
- Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
- Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
- LegitScript verified
- Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
- Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health
Where it loses points
- Legal entity name and state of incorporation not publicly disclosed
- The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
- Per-state availability not listed
- $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
- Lab work and dose-titration support not clearly described
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.